Recently, PLCγ1 inhibition has emerged as a therapeutic target for hematologic cancers and PLCγ1 phosphorylation status is a biomarker for metastatic risk in luminal breast cancer [11, 42, 43]. This evidence concerns the gene PLCG1 and hematopoietic and lymphoid cell neoplasm.